Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialSebastian Stintzing, Volker Heinemann, Alexander Kiani et al.|Annals of Oncology|2019Cited by 194
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al.|British Journal of Cancer|2020Cited by 187
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C. Kluin‐Nelemans, Martin Dreyling, Eva Hoster et al.|Journal of Clinical Oncology|2019Cited by 143